The transcriptional activity of the tumour suppressor, p53, requires direct binding between its transactivation domain (TAD, 1-57) and the transcriptional coactivator, p300. We systematically assessed the role of TAD phosphorylation on binding of the p300 domains CH3, Taz1, Kix and IBiD. Thr18 phosphorylation increased the affinity up to sevenfold for CH3 and Taz1, with smaller increases from phosphorylation of Ser20, Ser15, Ser37, Ser33, Ser46 and Thr55. Binding of Kix and IBiD was less sensitive to phosphorylation. Strikingly, hepta-phosphorylation of all Ser and Thr residues increased binding 40-and 80-fold with CH3 and Taz1, respectively, but not with Kix or IBiD. Substitution of all phospho-sites with aspartates partially mimicked the effects of hepta-phosphorylation. Mdm2, the main negative regulator of p53, competes with p300 for binding to TAD. Binding of Mdm2 to TAD was reduced significantly only on phosphorylation of Thr18 (sevenfold) or by hepta-phosphorylation (24-fold). The relative affinities of Mdm2 and p300 for p53 TAD can thus be changed by up to three orders of magnitude by phosphorylation. Accordingly, phosphorylation of Thr18 and hepta-phosphorylation dramatically shifts the balance towards favouring the binding of p300 with p53, and is thus likely to be an important factor in its regulation.
p53 is a homotetrameric transcription factor, which is frequently mutated in human cancers. In response to DNA damage and other stresses, p53 is stabilized and it activates diverse genes involved in cell cycle arrest, apoptosis, senescence and metabolism. p53 upregulation occurs through a variety of DNA damage-induced post-translational modifications that include phosphorylation, acetylation, methylation, neddylation and sumoylation (for reviews see Lavin and Gueven, 2006; Toledo and Wahl, 2006) .
The intrinsically disordered p53 transactivation domain (TAD) is essential for p53 transcriptional activity, as its direct interactions with the acetyltransferase activity-containing coactivator proteins, p300/CBP (as well as components of the basal transcriptional machinery), link the p53 target gene binding to p53 target gene expression. (Figures 1a and b) (Thut et al., 1995; Lill et al., 1997) . TAD also binds to the negative regulators, Mdm2 and Mdmx, which are competitive inhibitors of p53 binding, and Mdm2 facilitates C-terminal ubiquitination and subsequent p53 degradation (Marine and Jochemsen, 2004; Toledo and Wahl, 2006) . Concurrent phosphorylation of p53 TAD with DNA damage prompted numerous studies using mutational approaches to define the roles of individual TAD phosphorylations in vivo. Collectively, each phosphorylation site has apoptotic and/or cell cycle arrestinducing functions ascribed (Lavin and Gueven, 2006) . There are also modest cell cycle arrest and apoptotic defects in mouse knock-ins with mutations of Ser18/23, which are both conserved in humans (Ser15/Ser20) (Johnson and Attardi, 2006) . Phosphorylation of short peptides of p53 TAD1 (residues 15-29, 1-39) increases binding to p300/CBP (Dornan and Hupp, 2001; Polley et al., 2008) , and Ser15 phosphorylation increases p300 binding in vivo (Lambert et al., 1998) . However, several studies have questioned the requirement of p53 phosphorylation in p53 activation altogether, as mutation of all Ser/Thr in p53 TAD in stable cell lines does not impair p53's stability and transactivation potential (Ashcroft et al., 1999; Blattner et al., 1999) .
To address the question of the role of TAD phosphorylation at the molecular level, we dissected the effects of its phosphorylation on binding to its partner proteins; p300, being an essential positive effector for p53 activity, interacts with the full TAD (1-57) through four domains, Taz2/CH3, Taz1/CH1, Kix and IBiD (Figure 1b ) Teufel et al., 2007) . Conversely, the negative regulator, Mdm2, interacts with a shorter segment of TAD (15-29) (Sakaguchi et al., 2000; Schon et al., 2002) . We systematically assessed the role of each phosphorylation by comparing the affinities of different TAD (phospho-) peptides for those p300 domains and for Mdm2. Although all experiments were run in physiological ionic strength buffer, absolute affinities between the proteins may be different within cells. However, the relative affinities between wild type (WT) and phospho-peptides should be transferable to the full-length protein interactions within the cells, regardless of whether the interactions occur elsewhere on the proteins, and regardless of whether other factors contribute to them. Further, TAD has a similarly disordered structure to that in full-length p53 (Wells et al., 2008) . As the affinity of acidic TADs from transcription factors to transcriptional machinery proteins correlates with transcriptional activity (Melcher, 2000) , the use of peptides to assess the role of TAD phosphorylation presents an appropriate system for the evaluation of p53 phosphorylation in the context of p53 transactivation.
Seven TAD phospho-derivatives were generated (denoted as 1-57 S15(P), T18(P), S20(P), S33(P), S37(P), S46(P) and T55(P)), in which all phospho-sites reside within the p300 domain-binding interfaces. Using a C-terminal fluorophore (Lys-methoxycoumarin) as a probe on all peptides, their affinities for the isolated p300 and Mdm2 domains were determined by fluorescence anisotropy titrations as described in our earlier study (Teufel et al., 2007) .
Cysteine-histidine-rich region (CH)3 binds to 1-57 WT p53 the tightest (K D ¼ 18 nm). S15 and T18 phosphorylation induced the greatest increase in affinity for CH3 (K D ¼ 2.8 and 3.6 nM, respectively), which was 6.3-and 5-fold tighter than that for WT p53. Phosphor-ylation at S20, S33 or S37 caused a three-to fivefold increase in affinity. S46 or T55 phosphorylation gave a modest o twofold increase ( Figure 2a , Table 1 ).
Taz1, of a similar sequence as Taz2, also interacts strongly with 1-57 p53 (K D ¼ 770 nM). Here, T18 or S20 phosphorylation increased binding most significantly (K D ¼ 110 and 130 nM, respectively), with smaller increases for the remaining phospho-variants of p53 (1.5-to 4-fold) ( Figure 2b , Table 1 ). Phosphorylations at S46 or T55 again had the least effect on Taz1 binding.
Both Kix and IBiD bind more weakly to TAD (K D ¼ 3700 and 4400 nM, respectively). There were up to threefold increase in the affinity for Kix on phosphorylation at S15, T18, S20, S33 or S37. The same phosphorylations affected IBiD binding up to 1.6-fold. T18 or S20 phosphorylation increased Kix-binding the most, whereas binding of IBiD was affected equally by any of these phosphorylations. Interestingly, phosphorylation at S46 or T55 mildly reduced the affinity to both Kix and IBiD (Figures 2c and d , Table 1 ).
A less conserved region located between Taz1 and Kix (termed IBiD homology domain (IHD), Figure 1b ) has been reported to bind to 1-39 p53 (phospho-)peptides (Dornan et al., 2003; Polley et al., 2008) . Using NMR (nuclear magnetic resonance spectroscopy), we were unable Figure 1 (a) Sequence alignment of vertebrate p53 N-termini. Serines and threonines that are within the segment of p53 trans activating domain (TAD) contacted by p300 domains are in bold, and encircled by grey boxes. Kinases involved in their phosphorylation are shown above (Xu, 2003; Lavin and Gueven, 2006; Toledo and Wahl, 2006) . p53 L22/W23 and W53/F54, which are required for p53-p300 binding and transcriptional activity, are underlined. The approximate boundaries of p53 transactivation subdomains, TAD1 and TAD2, are shown below (dotted boxes), which are compared with the approximate extent of the p300/Mdm2/ Mdmx/p62 contact regions (black boxes). (b) Domain structure of p300. Taz1 is often referred to as cysteine-histidine-rich region 1 (CH1), PHD as CH2 and ZZ-Taz2 as CH3. Taz2 alone is responsible for the interaction with p53 TAD (Legge et al., 2004; Teufel et al., 2007) . to detect the folded structure in IHD, and anisotropy titration showed no detectable binding with any of the p53 (phospho-)peptides. p53 S15/S20 double phosphorylation is believed to enhance transcriptional activation (Xu, 2003; Chao et al., 2006) . The doubly phosphorylated peptide, p53 10-57 S15(P)/S20(P), bound no more tightly than either of the singly phosphorylated peptides (Table 1) .
In response to DNA damage, multiple phosphorylation occurs in p53 TAD, often in patterns depending on the nature of stress inflicted (Saito et al., 2003; Lavin and Gueven, 2006) . It was not feasible for us to test all possible permutations and combinations of phosphorylations of the seven sites, which would generate 127 different peptides. As most single phosphorylations increase the affinity of TAD for p300 (apart from S46/ T55), we reasoned that binding of the full heptaphosphorylated TAD to p300 domains would approximate to the highest possible affinity. We prepared the hepta-phosphorylated peptide of 10-57 p53 (denoted as 10-57 Hepta-(P)) by a combined chemical and enzymatic synthesis (Figure 3) . The hepta-phosphorylated peptide bound to CH3 B40-fold tighter than WT p53 (K D ¼ 530 pM) (Figure 2a ). Taz1 binding dramatically increased B80-fold (K D ¼ 11 nM); binding was >10-fold stronger than any single-phosphorylated peptide (Figure 2b) . Interestingly, p53 hepta-phosphorylation did not increase Kix and IBiD binding significantly (3.8-and 1.4-fold, respectively); affinities were roughly equivalent to those with the singly phosphorylated peptides (that is, T18(P)) ( Table 1, Figures 2c and d) . Consequently, Kix and IBiD are relatively insensitive to p53 phosphorylation. In contrast, the transcription factor CREB binds to Kix 150 times more tightly upon phosphorylation of a single residue (Ser133) (K D ¼ 0.7 mM) (Zor et al., 2002) . Thus, the phospho-serine selectivity observed with the Kix-CREB interaction is unique and cannot be generalized to p53.
Mutation of Ser or Thr to Asp generates 'phosphomimics' of p53 (Dornan and Hupp, 2001; Knights et al., 2003) . We made the hepta-substituted aspartate variant of p53 TAD (10-57 Hepta-(Asp)). It bound to CH3 and Taz1 11-and 23-fold more tightly than did WT TAD, respectively. Although binding of Hepta-(Asp) was stronger than that of WT or any singly phosphorylated peptide, it was still Bfourfold weaker than that of Hepta-(P), and so the Hepta-(Asp) derivative is a real, but partial, mimic.
We also tested a Ser/Thr-Ala-substituted derivative of p53 TAD (1-57 Hepta-(Ala)), which is used in cellbased and knock-in studies to assess the requirement of Ser/Thr phosphorylation in p53 (Blattner et al., 1999; Johnson and Attardi, 2006) . 1-57 Hepta-(Ala) bound to all domains at an affinity comparable with 1-57 WT p53, indicating that unphosphorylated Ser/Thr side chains of 1-57 p53 do not significantly contribute to the affinity for p300 (Table 1) .
Mdm2, the main negative regulator of p53, interacts through its N-terminal domain (1-125) with 15-29 p53 TAD1 (Figure 1a ). The interaction is strongly weakened by Thr18 phosphorylation (Lai et al., 2000; Sakaguchi et al., 2000; Schon et al., 2002; Brown et al., 2008) . However, regions C-terminal to TAD1 (30-57) weakly contribute to the p53-Mdm2 interaction (Chi et al., 2005; Teufel et al., 2007) . Consequently, we tested all peptides from this study to allow consistent comparison. As with the shorter 15-29 peptides, Thr18 phosphorylation in 1-57 peptides significantly weakened the interaction with Mdm2 (Table 1, Figure 2e ), whereas the variants 1-57 Hepta-(Ala) and 10-57 Ser15(P)/Ser20(P), had only small effects. Interestingly, hepta-phosphorylation reduced the affinity for Mdm2 B24-fold compared with the sevenfold reduction seen with Thr18 phosphorylation alone (K D ¼ 4700 nM, compared with K D ¼ 1300 nM for 1-57 T18(P)) ( Table 1) . Consistent with this, hepta-aspartylation strongly reduced binding (10-fold), but not as efficiently as heptaphosphorylation.
For ease of comparison, we plotted the change in binding energy in response to phosphorylation against 2.75 S15(P) T18(P) S33(P) S20(P) S37(P) S46(P) T55(P) 15/20(P) 7-(P) 7-(Asp) 7-(Ala)
Comparison of the effect of p53 phospho-derivatives against wild-type (WT) p53 for p300/Mdm2 domain binding. DDG refers to the difference in free binding energy between p53 phospho-derivative and WT p53 peptide for any of the binding proteins. The bars shown, therefore, represent the free binding energy contributed by a phosphorylation (or Asp, Ala substitution as with 7-(Asp) and 7-(Ala)). DG was calculated by -RT lnK D , and DDG was calculated by -RT ln(K D,WT /K D,variant ). Standard errors were determined as described earlier (Teufel et al., 2003) .
Figure 3 MALDI TOF mass spectra of kinase-phosphorylated 10-57 S15(P). p53 10-57 S15(P) peptide was successively phosphorylated by casein kinase I, casein kinase II (New England Biolabs, Ipswich, MA, USA) and c-jun N-terminal kinase (JNK) (Millipore, Watford, UK). Each enzyme phosphorylates three, two and one serine or threonine residue, respectively. Repeated rounds of kinase phosphorylations produced the final product, which is phosphorylated on all available seven Ser/Thr on p53 TAD. The presence of the respective mono-to hepta-phosphorylated peptides are colour-coded onto the mass spectra, with molecular weights shown on the top left of this figure. Mass peaks are broad due to the presence of multiple ionic salt species. Kinase reactions were carried out for 24 h at 30 1C according to the manufacturer's instructions, using (per ml) 200 mM peptide, 100 ml of 100 mM Mg-ATP, 10 ml enzyme, 2 ml EDTA-free protease inhibitor (Roche, Basel, Switzerland) and 1 ml b-mercaptoethanol. The final product was purified as described above and consisted mostly of hepta-phosphorylated products, as confirmed by MALDI-TOF (Voyager DE Pro, Applied Biosystems, Foster City, CA, USA), with small fractions of lower phospho-species.
the p53-phosphorylated residue and protein domain was investigated (Figure 4 ). The order of preference for any single TAD phosphorylation is roughly equivalent for all p300 domains. Strikingly, the tighter p53 interactors (CH3 and Taz1) were more sensitive to p53 single phosphorylation, particularly of S15, T18, S20, S33 and S37.
Assuming that the effect of a given phosphorylation on binding each of the four p300 domains is additive and applicable to the whole p300 protein, p53 T18 phosphorylation stands out as the greatest enhancer of p300 binding ( Figure 5) . The greater effect of single phosphorylations on S15/T18/S20 is interesting, as these residues are 100% conserved in all mammals (Figure 1a ). The smaller effects of S46/T55 phosphorylation correlate with little sequence conservation outside the primate species, suggesting that S46/T55 and their phosphorylation have not evolved to specifically enhance p300 binding (Figures 1a and 5) .
The full hepta-phosphorylation of p53 TAD drastically increased binding to CH3 and Taz1, but not to Kix and IBiD. The magnitude of binding enhancement (40-/ 80-fold) is comparable with the Ser133 phosphorylationenhanced CREB-Kix interaction, in which affinity increases B150-fold. Thus, p300 is a transcriptional adaptor protein that responds to transcription factor phosphorylation through at least three domains (Taz2/ CH3, Taz1, Kix).
The experimentally determined change in binding energy (DDG) for seven phosphorylations on the same peptide (Figure 4) is smaller than the sum of DDG for the seven individually phosphorylated peptides (DDG Hepta-(P) EÀ2.5 kcal/mol{S[DDG S15(P), T18(P), S20(P), S33(P), S37(P), S46(P), T55(P) ]EÀ5 kcal/mol for both CH3 and Taz1), indicating that the effects of single phosphoryla-tions are not additive with any of the p300 domains. Therefore, p300 domains are unlikely to have seven independent p53 phospho-group recognition sites. We suggest a loosely defined p300 domain-p53 scaffold-in which the hydrophobic residues L22/W23/W53/F54 of p53 are central to the interaction (Teufel et al., 2007) , and in which neighbouring phosphate groups, irrespective of their positions on p53 TAD, are flexibly accommodated (unpublished NMR data).
Our data suggest modulatory effects of 15, 20, 33 and 37 phosphorylations on p300 binding, whereas the binding of the p53 negative regulator, Mdm2, remains unaffected. It is possible, however, that other proteins from the transcriptional machinery (Tfb1, Taf9, etc) mediate specific effects of these phosphorylations (Lu and Levine, 1995; Di Lello et al., 2006) . Thr18 phosphorylation stands out as uniquely disrupting the interaction with Mdm2, whereas strongly increasing the binding to p300 (Figure 4 ). The T18(P)-induced difference in binding between Mdm2 and CH3/Taz1 was exacerbated by factors of B40-fold, as opposed to o sevenfold for any of the other single phosphorylations that do not affect Mdm2 binding (Table 1) . Notably, the mutant T18A p53 in p53 null cells is stabilized 5-10 times less efficiently than WT p53, and transcriptional activation of p53 target genes is severely impaired (Bean and Stark, 2002) . Conversely, the phospho-mimic, T18E p53, recovered p300 binding, reduced Mdm2 binding and reactivated p21 transcription in cancerous cells (Knights et al., 2003) . Thus, the quantitatively determined in vitro effects of p53 T18 phosphorylation on p300/Mdm2 binding correlate with the effects of T18 phosphorylation in vivo. Given the importance of T18 phosphorylation in binding p300, Mdm2 and Mdmx (Bottger et al., 1999) , it will be of interest to generate the corresponding knock-in mice (T21A and T21E) to assess their susceptibility to cancer development.
Although hepta-phosphorylation has not been specifically described in the literature, it is known that multiple phosphorylations can occur simultaneously on many residues of the p53 N-and C-termini (Saito et al., 2003; Lavin and Gueven, 2006) . Our data show that p53 TAD at the maximal possible phosphorylation state dramatically exacerbates the difference in affinity between Mdm2, and p300 CH3 (B900-fold) and Taz1 (B1900-fold) ( Table 1) . Given the competition of p300 and Mdm2 for p53 TAD (Oliner et al., 1993; Teufel et al., 2007) , the far tighter binding of hepta-phosphorylated p53 (or even the aspartylated derivative) to p300 should significantly increase the fraction of p53 bound to p300. Within the cellular context, T18 or hyperphosphorylation of p53 may thus lead to the upregulation of p53-dependent transcription of cell-cycle arrest and apoptotic genes.
Abbreviations CH1/CH3, cysteine-histidine-rich regions 1 and 3; TAD, p53 transactivation domain. Figure 5 Overall importance of single phosphorylations on p300 binding. The sum of DDG of a given phospho-peptide for all p300 domains shows the overall importance of a phosphorylation on p300 binding.
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